Drug Profile


Latest Information Update: 30 Jan 2004

Price : $50

At a glance

  • Originator Unknown
  • Developer Nonindustrial source; Unknown
  • Class Analgesics; Antihyperglycaemics
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic neuropathies; Neuropathic pain

Most Recent Events

  • 30 Jan 2004 Discontinued - Preclinical for Neuropathic pain in United Kingdom (unspecified route)
  • 30 Jan 2004 Discontinued for Diabetic neuropathies (unspecified route)
  • 15 Sep 1999 No-Development-Reported for Neuropathic pain in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top